Interleukin-1 beta (IL-1B), Interleukin-6 (IL-6), and Tumor necrosis factor alpha (TNF-A) (IL-1B/IL-6/TNF-A)

Pro-inflammatory cytokines, specifically Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), and Tumor Necrosis Factor alpha (TNF-α), are pivotal signaling proteins that coordinate the body's inflammatory and immune responses [1]. These molecules are primarily produced by activated macrophages, monocytes, and dendritic cells in response to pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) [2]. IL-1β is a potent pyrogen and mediator of the inflammasome pathway, while IL-6 is the primary driver of the hepatic acute-phase response and B-cell maturation [3, 4]. TNF-α acts as a master regulator, inducing the expression of other cytokines and adhesion molecules, and can trigger programmed cell death [5]. Chronic overproduction of these cytokines is central to the pathogenesis of numerous autoimmune and autoinflammatory diseases, including rheumatoid arthritis, Crohn's disease, and cytokine release syndrome [6]. Therapeutic intervention typically involves the use of biologic agents, such as monoclonal antibodies (e.g., adalimumab, tocilizumab) or receptor antagonists (e.g., anakinra), to neutralize these proteins or block their signaling [7]. While these therapies are highly effective, they carry significant risks, most notably an increased susceptibility to serious opportunistic infections and the potential for malignancy [8].

Other names

Pro-inflammatory cytokinesInflammatory triadIL-1BIL-6TNF-alphaCachectin

Neutralization of soluble and membrane-bound cytokines via monoclonal antibodies, competitive inhibition of cytokine receptors, or sequestration by soluble decoy receptors.